Upon completion of the intervention, i.e., at 6 months of age, the Myh6-Cre:DspW/F mice in the untreated or the placebo group had developed cardiac dilatation and dysfunction, as compared to the corresponding WT mice, as evidenced by increased LVEDD, LVESD, and reduced FS, which are consistent with the published data [Table 1][21,30]. The gene discussed is MYH6; the disease is Vascular dilatation.